Condition: Asthma; Eosinophilic · Severe Asthma · Sponsor: Nantes University Hospital
The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients. This trial is a French, multicenter and no-randomized trial. Patients enrolled will be clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6 clinical visit on site and in phone call at 13 months)
This description comes directly from the study's public registry record.
François-Xavier BLANC, MD-PHD · +33240165545 · xavier.blanc@chu-nantes.fr
Always discuss trial participation with your own doctor first.
| Centre hospitalier Intercommunal Aix-en-Provence | Aix-en-Provence, France | Recruiting |
| CHU Angers | Angers, France | Recruiting |
| CHU Bordeaux | Bordeaux, France | Recruiting |
| CHRU Brest | Brest, France | Recruiting |
| CHU Dijon | Dijon, France | Recruiting |
| CHU Grenoble | Grenoble, France | Recruiting |
| Hôpital Bicêtre - AP-HP | Le Kremlin-Bicêtre, France | Recruiting |
| CH Mans | Le Mans, France | Withdrawn |
| CHU Lille | Lille, France | Withdrawn |
| Hospices Civils de Lyon | Lyon, France | Recruiting |
| Assistance Publique des Hôpitaux de Marseille | Marseille, France | Not Yet Recruiting |
| CHU Montpellier | Montpellier, France | Withdrawn |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04565483